SGLT2 are a promising new class of diabetes pharmacotherapy that particularly shows favorable effects on weight, low potential of hypoglycemia and a reduction of cardiovascular risk [2, 4, 5]. The gene discussed is SLC5A2; the disease is diabetes mellitus.